Evobrutinib

Merck KGaA confirms advanced acquisition discussions with SpringWorks Therapeutics, though critical conditions remain unmet and no binding agreement has been reached.

The FDA has granted Breakthrough Therapy designation to tolebrutinib for adults with non-relapsing secondary progressive multiple sclerosis (nrSPMS).

Genetic risk factors for MS were traced back to migrations 5,000 years ago, offering insights into disease origins.

A comprehensive systematic review of phase II and III clinical trials for relapsing multiple sclerosis (RMS) has been conducted, focusing on trial designs and primary endpoints. The review, which analyzed 60 trials from three major trial registration systems, highlights the dominance of randomized controlled parallel-arms trials and discusses the most common primary endpoints across different trial phases and patient groups. The findings suggest a need for revisions in regulatory guidelines and expert recommendations to better align with current clinical trial practices.